Tag: dr. reddy’s

Dr. Reddy’s acquiring Mayne Pharma’s U.S. generic portfolio for million

Dr. Reddy’s acquiring Mayne Pharma’s U.S. generic portfolio for $90 million

cpooldigitalLeave a Comment on Dr. Reddy’s acquiring Mayne Pharma’s U.S. generic portfolio for $90 million

Representational image only. | Photo Credit: Special Arrangement Pharma major Dr. Reddy’s Laboratories is acquiring the U.S. generic prescription product portfolio of Australia’s Mayne Pharma Group for an upfront cash consideration of around $90 million. The portfolio includes 45 commercial products, four pipeline products and 40 approved non-marketed products, including generic products focussed on women’s […]

Continue Reading
Dr. Reddy’s completes Phase 1 study of proposed biosimilar of tocilizumab

Dr. Reddy’s completes Phase 1 study of proposed biosimilar of tocilizumab

cpooldigitalLeave a Comment on Dr. Reddy’s completes Phase 1 study of proposed biosimilar of tocilizumab

Dr. Reddy’s Laboratories shares gained on Monday in the backdrop of the drugmaker announcing successful completion of a phase-1 study of its proposed biosimilar of tocilizumab for use in the treatment of rheumatoid arthritis. DRL_TC, the biosimilar candidate, successfully met its primary and secondary endpoints in a Phase 1 study that used a subcutaneous formulation […]

Continue Reading
Dr. Reddy’s faces anti-trust litigation in U.S. over cancer drug Revlimid

Dr. Reddy’s faces anti-trust litigation in U.S. over cancer drug Revlimid

cpooldigitalLeave a Comment on Dr. Reddy’s faces anti-trust litigation in U.S. over cancer drug Revlimid

A bottle of Revlimid and pills are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S. File | Photo Credit: Reuters Dr. Reddy’s Laboratories and a few other drugmakers have been named defendants in a complaint filed in the U.S. under the Federal and State antitrust laws […]

Continue Reading
Dr. Reddy’s completes Phase 1 study of proposed biosimilar of tocilizumab

Intercept Pharmaceuticals settles Ocaliva patent litigation case with Dr. Reddy’s

cpooldigitalLeave a Comment on Intercept Pharmaceuticals settles Ocaliva patent litigation case with Dr. Reddy’s

For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to the prior year For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to […]

Continue Reading
Dr. Reddy’s to acquire Slayback’s eyedrop rights

Dr. Reddy’s to acquire Slayback’s eyedrop rights

cpooldigitalLeave a Comment on Dr. Reddy’s to acquire Slayback’s eyedrop rights

Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain rights to New Jersey-based Slayback Pharma’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Slayback Pharma is the first to file an ANDA (abbreviated new drug application) for the private label equivalent for Lumify with the U.S. Food and Drug Administration (USFDA) under Paragraph IV […]

Continue Reading
Suboxone settlement boosts Dr. Reddy’s Q1 net

Suboxone settlement boosts Dr. Reddy’s Q1 net

cpooldigitalLeave a Comment on Suboxone settlement boosts Dr. Reddy’s Q1 net

Proceeds from a settlement pact with British drugmaker lndivior and its strategy of divesting brands to sharpen focus on core products aided pharma major Dr. Reddy’s Laboratories in reporting manifold increase in consolidated net profit to ₹1,189 crore for the first quarter. Besides contributing to the sharp rise from ₹380.4 crore of the year-earlier period, […]

Continue Reading